Cargando…

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

Programmed cell death-1 (PD-1) and/or cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint inhibitor (ICI) treatments are associated with adverse events (AEs), which may be dependent on ICI dose. Applying a model-based meta-analysis to evaluate safety data from published clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shulgin, Boris, Kosinsky, Yuri, Omelchenko, Andrey, Chu, Lulu, Mugundu, Ganesh, Aksenov, Sergey, Pimentel, Rodrigo, DeYulia, Garrett, Kim, Geoffrey, Peskov, Kirill, Helmlinger, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466858/ https://www.ncbi.nlm.nih.gov/pubmed/32934874 http://dx.doi.org/10.1080/2162402X.2020.1748982

Ejemplares similares

A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies
por: Shulgin, Boris, et al.
Publicado: (2016)

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Evaluation of Combination Strategies for the A(2A)R Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model
por: Voronova, Veronika, et al.
Publicado: (2021)

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study
por: Azarov, Ivan, et al.
Publicado: (2019)

Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab
por: Gavrilov, Sergey, et al.
Publicado: (2020)

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model
por: Kosinsky, Yuri, et al.
Publicado: (2018)

Cycle Network Model of Prostaglandin H Synthase-1
por: Goltsov, Alexey, et al.
Publicado: (2020)

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
por: Helmlinger, Gabriel, et al.
Publicado: (2019)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?
por: Voronova, Veronika, et al.
Publicado: (2017)

A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics
por: Zhudenkov, Kirill, et al.
Publicado: (2022)

Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis
por: Voronova, Veronika, et al.
Publicado: (2020)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Agent Based Modeling of Human Gut Microbiome Interactions and Perturbations
por: Shashkova, Tatiana, et al.
Publicado: (2016)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab
por: Dey, Agnish, et al.
Publicado: (2022)

A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings
por: Voronova, Veronika, et al.
Publicado: (2020)

Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients
por: Salem, Ahmed M., et al.
Publicado: (2023)

Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
por: Voronova, Veronika, et al.
Publicado: (2022)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Management of the Adverse Effects of Immune Checkpoint Inhibitors
por: Morgado, Manuel, et al.
Publicado: (2020)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
por: Paluri, Ravi Kumar, et al.
Publicado: (2023)

North Pacific Baleen Whales as a Potential Source of Persistent Organic Pollutants (POPs) in the Diet of the Indigenous Peoples of the Eastern Arctic Coasts
por: Chukmasov, Pavel, et al.
Publicado: (2019)

PeTTSy: a computational tool for perturbation analysis of complex systems biology models
por: Domijan, Mirela, et al.
Publicado: (2016)

Management of adverse events related to checkpoint inhibition therapy
por: Rudzki, Jakob Daniel
Publicado: (2018)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
por: Vani, Vanina, et al.
Publicado: (2020)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

COVID-19 and excess mortality in Russia: Regional estimates of life expectancy losses in 2020 and excess deaths in 2021
por: Scherbov, Sergei, et al.
Publicado: (2022)

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
por: Chen, Joseph, et al.
Publicado: (2021)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
por: Poto, Remo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ul5p616jerpsek44fh07h7msmq